Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Candotti

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
American Journal of Medical Genetics. Part A|August 20, 2015
NBAS mutations cause a multisystem disorder involving bone, connective tissue, liver, immune system, and retinaNuria Garcia Segarra, Diana Ballhausen, Heather Crawford, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
The Journal of Experimental Medicine|September 16, 2015
Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndromeNikita S Kolhatkar, Archana Brahmandam, Christopher D Thouvenel, et al.
Scientific Reports|May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteersYves Levy, Christiane Moog, Aurélie Wiedemann, et al.
The Journal of Experimental Medicine|July 8, 2015
Reticular dysgenesis-associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stressAlberto Rissone, Katja Gabriele Weinacht, Giancarlo la Marca, et al.
Blood|September 16, 2006
Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case reportBarbara C Engel, Greg M Podsakoff, Joanna L Ireland, et al.
Blood|November 29, 2002
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trialLinda Mesler Muul, Laura M Tuschong, Sherry Lau Soenen, et al.
Journal of Clinical Immunology|April 16, 2015
Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioningMakoto Otsu, Masafumi Yamada, Satoru Nakajima, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2009
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and managementLinda M Griffith, Morton J Cowan, Luigi D Notarangelo, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2015
Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopeniaElena Crestani, Stefano Volpi, Fabio Candotti, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
American Journal of Medical Genetics. Part A|August 20, 2015
NBAS mutations cause a multisystem disorder involving bone, connective tissue, liver, immune system, and retinaNuria Garcia Segarra, Diana Ballhausen, Heather Crawford, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
The Journal of Experimental Medicine|September 16, 2015
Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndromeNikita S Kolhatkar, Archana Brahmandam, Christopher D Thouvenel, et al.
Scientific Reports|May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteersYves Levy, Christiane Moog, Aurélie Wiedemann, et al.
The Journal of Experimental Medicine|July 8, 2015
Reticular dysgenesis-associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stressAlberto Rissone, Katja Gabriele Weinacht, Giancarlo la Marca, et al.
Blood|September 16, 2006
Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case reportBarbara C Engel, Greg M Podsakoff, Joanna L Ireland, et al.
Blood|November 29, 2002
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trialLinda Mesler Muul, Laura M Tuschong, Sherry Lau Soenen, et al.
Journal of Clinical Immunology|April 16, 2015
Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioningMakoto Otsu, Masafumi Yamada, Satoru Nakajima, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2009
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and managementLinda M Griffith, Morton J Cowan, Luigi D Notarangelo, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2015
Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopeniaElena Crestani, Stefano Volpi, Fabio Candotti, et al.
Pageof 15